Please assess the completion status of the following clinical trial:

Trial Title: PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with known coronary artery disease (defined as prior type I myocardial infarction, coronary revascularization, percutaneous or surgical, or presence of at least a 50% stenosis in any major epicardial vessel).~* Age \> 18 years old~* On aspirin 81mg/qd for at least 1 month~Exclusion criteria:~* Inability to provide written informed consent~* Hemodynamic instability~* On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in past 30 days~* Known allergies to ticagrelor or cangrelor~* Considered at high risk for bleeding~* History of intracranial bleeding/hemorrhagic stroke~* On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxoban) within past 30 days~* Known platelet count \<80x106/mL~* Known hemoglobin \<10 g/dL~* Active bleeding~* Known end stage renal disease on hemodialysis~* Known severe hepatic dysfunction~* Acute or severe bronchial asthma or upper airway obstruction.~* Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.~* Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.~* Pregnant females \[women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cangrelor (Type: EXPERIMENTAL): Ticagrelor loading dose followed after 1 hour by cangrelor bolus and infusion
- Placebo (Type: PLACEBO_COMPARATOR): Ticagrelor loading dose followed after 1 hour by placebo infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).